{"id":"bms-986177","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BMS-986177 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing T cell activation and proliferation. This leads to an increase in anti-tumor immune responses.","oneSentence":"BMS-986177 is an anti-PD-1 monoclonal antibody.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:12.356Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT05754957","phase":"PHASE3","title":"A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-07","conditions":"Acute Coronary Syndrome","enrollment":14194},{"nctId":"NCT05702034","phase":"PHASE3","title":"A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-02-15","conditions":"Ischemic Stroke; Ischemic Attack, Transient","enrollment":15000},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT04844424","phase":"PHASE1","title":"A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-04-14","conditions":"Healthy","enrollment":115},{"nctId":"NCT04223349","phase":"PHASE1","title":"A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-01-10","conditions":"Healthy","enrollment":66},{"nctId":"NCT05706753","phase":"PHASE1","title":"A Study of Milvexian in Healthy Adult Females","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2023-01-25","conditions":"Healthy Female","enrollment":20},{"nctId":"NCT04388501","phase":"PHASE1","title":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2021-06-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT04206488","phase":"PHASE1","title":"A Study of JNJ-70033093 and Digoxin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-01-09","conditions":"Healthy","enrollment":30},{"nctId":"NCT03891524","phase":"PHASE2","title":"A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-17","conditions":"Arthroplasty, Replacement, Knee","enrollment":1242},{"nctId":"NCT04569695","phase":"PHASE1","title":"A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT04448964","phase":"PHASE1","title":"A Study of JNJ-70033093 in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-26","conditions":"Healthy","enrollment":24},{"nctId":"NCT04965389","phase":"PHASE1","title":"A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2021-07-16","conditions":"Healthy Volunteers","enrollment":17},{"nctId":"NCT03766581","phase":"PHASE2","title":"A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-01-27","conditions":"Acute Ischemic Stroke, Transient Ischemic Attack (TIA)","enrollment":2366},{"nctId":"NCT03196206","phase":"PHASE1","title":"Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-13","conditions":"Thrombosis","enrollment":24},{"nctId":"NCT03698513","phase":"PHASE1","title":"A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-10-04","conditions":"Healthy Volunteers","enrollment":113},{"nctId":"NCT03000673","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-05-23","conditions":"Antithrombotic","enrollment":32},{"nctId":"NCT03939702","phase":"PHASE1","title":"Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-05-02","conditions":"Thrombosis","enrollment":9},{"nctId":"NCT02982707","phase":"PHASE1","title":"Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-01","conditions":"Thrombosis","enrollment":26},{"nctId":"NCT03224260","phase":"PHASE1","title":"To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-06-28","conditions":"Thrombosis","enrollment":33},{"nctId":"NCT03362437","phase":"PHASE1","title":"Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-15","conditions":"Thrombosis","enrollment":12},{"nctId":"NCT03341390","phase":"PHASE1","title":"An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-10-18","conditions":"Healthy Volunteers","enrollment":20},{"nctId":"NCT02608970","phase":"PHASE1","title":"Safety and Tolerability Study of BMS-986177 in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Thrombosis","enrollment":104},{"nctId":"NCT02902679","phase":"PHASE1","title":"A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11","conditions":"Thrombosis, Factor XI, Renal Impairment","enrollment":6},{"nctId":"NCT02959060","phase":"PHASE1","title":"A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-11","conditions":"Thrombosis","enrollment":16},{"nctId":"NCT02807909","phase":"PHASE1","title":"A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-07","conditions":"Thrombosis","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Milvexian, JNJ-70033093"],"phase":"phase_2","status":"active","brandName":"BMS-986177","genericName":"BMS-986177","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986177 is an anti-PD-1 monoclonal antibody. Used for Non-small cell lung cancer, Melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":10,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}